<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827930</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-07</org_study_id>
    <secondary_id>2008-007094-20</secondary_id>
    <nct_id>NCT01827930</nct_id>
  </id_info>
  <brief_title>Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response</brief_title>
  <acronym>MIM</acronym>
  <official_title>Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with&#xD;
      CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response&#xD;
      and major molecular response rate) is dependent on the residual plasma Imatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with&#xD;
      CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response&#xD;
      and major molecular response rate) is dependent on the residual plasma Imatinib. This study&#xD;
      aims to evaluate the effectiveness of a strategy for dose adjustment of Imatinib Mesylate&#xD;
      based on the measurement of the residual plasma imatinib in patients treated for at least 2&#xD;
      years Imatinib 400 mg / d in complete cytogenetic response for at least 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties of enrolment of Patient&#xD;
  </why_stopped>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>IM concentration &lt; 1000ng/mL Randomized Cohort : &quot;adapted strategy&quot; versus &quot;standard strategy&quot; / IM concentration &gt;= 1000ng/mL Parallel Cohort: &quot;standard strategy&quot;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Presenting a Decline of the BCR-ABL Transcript Rate at 12 Months From Baseline - Randomised Study</measure>
    <time_frame>12 months</time_frame>
    <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Treatment is considered effective at 12 months if:&#xD;
for patients with an inclusion transcript rate less than 0.1%: the transcript rate at 12 months is less or equal to 0.001% or undetectable.&#xD;
for patients with an inclusion transcript rate greater than 0.1% : the transcript rate at 12 months is less or equal to 0.1% or undetectable.&#xD;
If BCR-ABL transcript level was unavailable at M12, the treatment was considered ineffective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline of 2-log of the BCR-ABL Transcript Rate at 3 ,6, 9 and 12 Months From Baseline - Randomised Study</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Efficacy was also evaluated at 3, 6, 9 and 12 months in terms of decreasing the rate of BCR-ABL transcripts of 2 logarithms, relative to the initial value (inclusion). The lack of data on the transcript rate was considered as failure (no decrease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response at 3, 6, 9 and 12 Months</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The molecular response is defined by the measurement of BCR-ABL transcript rate by quantitative RT-PCR (RQ-PCR) on peripheral venous blood according to international standards.&#xD;
It is defined as:&#xD;
Major Molecular Response (MMR): BRC-ABL transcript rate ≤ 0.1%&#xD;
Complete Molecular Response (CMR): transcript BCR-ABL undetectable and non quantifiable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Molecular Response (CMR) and Major Molecular Response (MMR)</measure>
    <time_frame>From date of randomization until the date of complete molecular response (up to 12 months)</time_frame>
    <description>Time to complete molecular response was defined by the time from inclusion/randomization and the first CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of BCR-ABL Undetectable</measure>
    <time_frame>12 first months</time_frame>
    <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First BCR-ABL Undetectable</measure>
    <time_frame>within 12 months following randomization</time_frame>
    <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Time to the first BCR-ABL undetectable was defined by the time from inclusion/randomization and the first CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>First 12 months</time_frame>
    <description>Overall survival is defined by the time from de date of inclusion/randomization to the date of death (of any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>First 12 months</time_frame>
    <description>Progression-free survival was defined by the time from the date of inclusion and the date of progression.&#xD;
Progression was defined as :&#xD;
Death,&#xD;
Passage into the acceleration phase defined by one of the following criteria: % of blood or medullary blasts greater than 15% but less than 30%, blasts plus promyelocytes greater than 30% in the blood or marrow, basophils greater than 20% in the blood, thrombocytopenia less than 100x10^9/L unrelated to treatment, clonal evolution)&#xD;
Passage to the blast transformation phase defined by one of the following criteria: % of blasts of blood or bone marrow greater than 30%, occurrence of extramedullary damage other than histologically proven hepato-splenic.&#xD;
Increase in BCR-ABL transcripts greater than or equal to 2-log compared to the previous values (this increase must be confirmed within 3 months).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Leukemia, Myeloid, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>Imatinib 600 (Randomized trial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib 400 (Randomized trial)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib400 (Cohort)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate 600 MG Oral Tablet</intervention_name>
    <description>Imatinib Mesylate for CP CML</description>
    <arm_group_label>Imatinib 600 (Randomized trial)</arm_group_label>
    <other_name>GLIVEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate 400 MG Oral Tablet</intervention_name>
    <description>Imatinib Mesylate for CP CML</description>
    <arm_group_label>Imatinib 400 (Randomized trial)</arm_group_label>
    <other_name>GLIVEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Imatinib Mesylate for CP CML</description>
    <arm_group_label>Imatinib400 (Cohort)</arm_group_label>
    <other_name>GLIVEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with CML-CP treated for at least two years by Imatinib Mesylate 400 mg / d,&#xD;
&#xD;
          2. Patients in complete cytogenetic response for at least 1 year&#xD;
&#xD;
          3. Patients with residual disease detectable by quantitative RT-PCR (RQ-PCR)&#xD;
&#xD;
          4. ECOG ≤ 2,&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. Signed informed consent,&#xD;
&#xD;
          7. Membership of a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with CML-CP Philadelphia chromosome negative diagnosis.&#xD;
&#xD;
          2. Patients previously treated with Imatinib Mesylate at doses above 400 mg / day&#xD;
&#xD;
          3. Patient with non-hematologic toxicity of grade III or IV in Imatinib Mesylate 400mg /&#xD;
             d&#xD;
&#xD;
          4. Patient with a medical condition endocrine, psychiatric, neurological, renal, hepatic&#xD;
             or cardiac progressive uncontrolled by medical treatment&#xD;
&#xD;
          5. Pregnant or breastfeeding women, women of childbearing potential not using a&#xD;
             contraceptive method effective&#xD;
&#xD;
          6. Known HIV positive&#xD;
&#xD;
          7. Patients previously treated with another tyrosine kinase inhibitor&#xD;
&#xD;
          8. Patient participating in another interventional clinical trial&#xD;
&#xD;
          9. History of non-compliance to Imatinib Mesylate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ETIENNE Gabriel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.e-cancer.fr/Professionnels-de-sante/Le-registre-des-essais-cliniques</url>
    <description>Registre des essais cliniques de l'INCa</description>
  </link>
  <link>
    <url>https://www.bergonie.fr/les-essais-cliniques</url>
    <description>Site internet du promoteur, l'Institut Bergonié</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myeloid leukemia in chronic phase</keyword>
  <keyword>residual plasma IM concentration</keyword>
  <keyword>adapted strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imatinib 600 (Randomized Trial)</title>
          <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="P2">
          <title>Imatinib 400 (Randomized Trial)</title>
          <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="P3">
          <title>Imatinib400 (Cohort)</title>
          <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
      <group_list>
        <group group_id="B1">
          <title>Imatinib 600 (Randomized Trial)</title>
          <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="B2">
          <title>Imatinib 400 (Randomized Trial)</title>
          <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="B3">
          <title>Imatinib400 (Parallel Cohort)</title>
          <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" lower_limit="27.7" upper_limit="72.0"/>
                    <measurement group_id="B2" value="52.7" lower_limit="25.1" upper_limit="79.1"/>
                    <measurement group_id="B3" value="65.3" lower_limit="34.3" upper_limit="80.4"/>
                    <measurement group_id="B4" value="54.5" lower_limit="25.1" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Presenting a Decline of the BCR-ABL Transcript Rate at 12 Months From Baseline - Randomised Study</title>
        <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Treatment is considered effective at 12 months if:&#xD;
for patients with an inclusion transcript rate less than 0.1%: the transcript rate at 12 months is less or equal to 0.001% or undetectable.&#xD;
for patients with an inclusion transcript rate greater than 0.1% : the transcript rate at 12 months is less or equal to 0.1% or undetectable.&#xD;
If BCR-ABL transcript level was unavailable at M12, the treatment was considered ineffective.</description>
        <time_frame>12 months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Presenting a Decline of the BCR-ABL Transcript Rate at 12 Months From Baseline - Randomised Study</title>
          <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Treatment is considered effective at 12 months if:&#xD;
for patients with an inclusion transcript rate less than 0.1%: the transcript rate at 12 months is less or equal to 0.001% or undetectable.&#xD;
for patients with an inclusion transcript rate greater than 0.1% : the transcript rate at 12 months is less or equal to 0.1% or undetectable.&#xD;
If BCR-ABL transcript level was unavailable at M12, the treatment was considered ineffective.</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="12.6" upper_limit="51.1"/>
                    <measurement group_id="O2" value="32.0" lower_limit="14.9" upper_limit="53.5"/>
                    <measurement group_id="O3" value="10.5" lower_limit="1.3" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline of 2-log of the BCR-ABL Transcript Rate at 3 ,6, 9 and 12 Months From Baseline - Randomised Study</title>
        <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Efficacy was also evaluated at 3, 6, 9 and 12 months in terms of decreasing the rate of BCR-ABL transcripts of 2 logarithms, relative to the initial value (inclusion). The lack of data on the transcript rate was considered as failure (no decrease).</description>
        <time_frame>3, 6, 9 and 12 months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline of 2-log of the BCR-ABL Transcript Rate at 3 ,6, 9 and 12 Months From Baseline - Randomised Study</title>
          <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Efficacy was also evaluated at 3, 6, 9 and 12 months in terms of decreasing the rate of BCR-ABL transcripts of 2 logarithms, relative to the initial value (inclusion). The lack of data on the transcript rate was considered as failure (no decrease).</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Molecular Response at 3, 6, 9 and 12 Months</title>
        <description>The molecular response is defined by the measurement of BCR-ABL transcript rate by quantitative RT-PCR (RQ-PCR) on peripheral venous blood according to international standards.&#xD;
It is defined as:&#xD;
Major Molecular Response (MMR): BRC-ABL transcript rate ≤ 0.1%&#xD;
Complete Molecular Response (CMR): transcript BCR-ABL undetectable and non quantifiable.</description>
        <time_frame>3, 6, 9 and 12 months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Molecular Response at 3, 6, 9 and 12 Months</title>
          <description>The molecular response is defined by the measurement of BCR-ABL transcript rate by quantitative RT-PCR (RQ-PCR) on peripheral venous blood according to international standards.&#xD;
It is defined as:&#xD;
Major Molecular Response (MMR): BRC-ABL transcript rate ≤ 0.1%&#xD;
Complete Molecular Response (CMR): transcript BCR-ABL undetectable and non quantifiable.</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>percentage of patient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months - CMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                    <measurement group_id="O2" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months : MMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="53.3" upper_limit="90.2"/>
                    <measurement group_id="O2" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                    <measurement group_id="O3" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months : CMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months : MMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O2" value="72.0" lower_limit="50.6" upper_limit="87.9"/>
                    <measurement group_id="O3" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months : CMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months : MMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                    <measurement group_id="O2" value="68.0" lower_limit="46.5" upper_limit="85.1"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months : CMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months : MMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                    <measurement group_id="O2" value="76.0" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O3" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Molecular Response (CMR) and Major Molecular Response (MMR)</title>
        <description>Time to complete molecular response was defined by the time from inclusion/randomization and the first CMR.</description>
        <time_frame>From date of randomization until the date of complete molecular response (up to 12 months)</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Molecular Response (CMR) and Major Molecular Response (MMR)</title>
          <description>Time to complete molecular response was defined by the time from inclusion/randomization and the first CMR.</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CMR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="3.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="3.2" lower_limit="3.1" upper_limit="5.5"/>
                    <measurement group_id="O3" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.7" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.3" upper_limit="6.1"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.1" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of BCR-ABL Undetectable</title>
        <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.</description>
        <time_frame>12 first months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of BCR-ABL Undetectable</title>
          <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="12.6" upper_limit="51.1"/>
                    <measurement group_id="O2" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First BCR-ABL Undetectable</title>
        <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Time to the first BCR-ABL undetectable was defined by the time from inclusion/randomization and the first CMR.</description>
        <time_frame>within 12 months following randomization</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First BCR-ABL Undetectable</title>
          <description>The BCR-ABL transcript rate was analysed by molecular biology by RQ-PCR at study entry, 3 months, 6 months, 9 months and 12 months.&#xD;
Time to the first BCR-ABL undetectable was defined by the time from inclusion/randomization and the first CMR.</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="3.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="3.2" lower_limit="3.1" upper_limit="5.5"/>
                    <measurement group_id="O3" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined by the time from de date of inclusion/randomization to the date of death (of any cause).</description>
        <time_frame>First 12 months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined by the time from de date of inclusion/randomization to the date of death (of any cause).</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival was defined by the time from the date of inclusion and the date of progression.&#xD;
Progression was defined as :&#xD;
Death,&#xD;
Passage into the acceleration phase defined by one of the following criteria: % of blood or medullary blasts greater than 15% but less than 30%, blasts plus promyelocytes greater than 30% in the blood or marrow, basophils greater than 20% in the blood, thrombocytopenia less than 100x10^9/L unrelated to treatment, clonal evolution)&#xD;
Passage to the blast transformation phase defined by one of the following criteria: % of blasts of blood or bone marrow greater than 30%, occurrence of extramedullary damage other than histologically proven hepato-splenic.&#xD;
Increase in BCR-ABL transcripts greater than or equal to 2-log compared to the previous values (this increase must be confirmed within 3 months).</description>
        <time_frame>First 12 months</time_frame>
        <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 (Randomized Trial)</title>
            <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 400 (Randomized Trial)</title>
            <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
          </group>
          <group group_id="O3">
            <title>Imatinib400 (Parallel Cohort)</title>
            <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival was defined by the time from the date of inclusion and the date of progression.&#xD;
Progression was defined as :&#xD;
Death,&#xD;
Passage into the acceleration phase defined by one of the following criteria: % of blood or medullary blasts greater than 15% but less than 30%, blasts plus promyelocytes greater than 30% in the blood or marrow, basophils greater than 20% in the blood, thrombocytopenia less than 100x10^9/L unrelated to treatment, clonal evolution)&#xD;
Passage to the blast transformation phase defined by one of the following criteria: % of blasts of blood or bone marrow greater than 30%, occurrence of extramedullary damage other than histologically proven hepato-splenic.&#xD;
Increase in BCR-ABL transcripts greater than or equal to 2-log compared to the previous values (this increase must be confirmed within 3 months).</description>
          <population>All patients included, regardless of whether or not treatment was administered, and regardless violations of any eligibility criteria. This population corresponds to Intention to treat population for randomized study, and population assessable for the primary endpoind for the parralel cohort.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>throughout the follow-up of the patient, up to 1 year</time_frame>
      <desc>All adverse envent (related and unrelated to treatment) were reported.&#xD;
All serious adverse envent (related and unrelated to treatment) were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Imatinib 600 (Randomized Trial)</title>
          <description>Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po&#xD;
Imatinib Mesylate 600 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="E2">
          <title>Imatinib 400 (Randomized Trial)</title>
          <description>Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate 400 MG Oral Tablet: Imatinib Mesylate for CP CML</description>
        </group>
        <group group_id="E3">
          <title>Imatinib400 (Parallel Cohort)</title>
          <description>Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po&#xD;
Imatinib Mesylate: Imatinib Mesylate for CP CML</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other (Specify, __)</sub_title>
                <description>CARDIAC GENERAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <description>CARDIAC GENERAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <description>INFECTION (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, __)</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, __)</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, __)</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, __)</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Blood and lymphatic system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other (Specify, __)</sub_title>
                <description>CARDIAC GENERAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <description>OCULAR/VISUAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, __)</sub_title>
                <description>OCULAR/VISUAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <description>OCULAR/VISUAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, __)</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stomach</sub_title>
                <description>PAIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema:head and neck</sub_title>
                <description>LYMPHATICS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema:limb</sub_title>
                <description>LYMPHATICS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify, __)</sub_title>
                <description>LYMPHATICS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <description>Immune system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <description>INFECTION (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <description>Blood and lymphatic system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Blood and lymphatic system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>Blood and lymphatic system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, __)</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint</sub_title>
                <description>PAIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Head/headache</sub_title>
                <description>PAIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>NEUROLOGY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, __)</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <description>Immune system disorders (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nose</sub_title>
                <description>HEMORRHAGE/BLEEDING (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, __)</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Induration/fibrosis (skin and subcutaneous tissue)</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>CARDIAC GENERAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Carotid</sub_title>
                <description>VASCULAR (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr Simone Mathoulin-Pelissier</name_or_title>
      <organization>Institut Bergonié</organization>
      <phone>05 56 33 33 33</phone>
      <email>S.Mathoulin@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

